Natural Pollen Exposure Increases the Response Plateau to Adenosine 5′-Monophosphate and Bronchial but Not Alveolar Nitric Oxide in Sensitized Subjects

V. Lopez a  L. Prieto b  C. Perez-Frances a  D. Barato a  J. Marin b

a Seccion de Alergologia, Hospital Dr. Peset, and b Universidad de Valencia, Valencia, Spain

Key Words
Adenosine 5′-monophosphate • Airway hyperresponsiveness • Exhaled breath condensate pH • Exhaled nitric oxide • Plateau nitric oxide concentration

Abstract
Background: The effect of allergen exposure on airway responsiveness and exhaled nitric oxide (NO) has been well documented, but no information is available on allergen-induced changes in the response plateau to adenosine 5′-monophosphate (AMP) and in bronchial NO flux (J′awNO) and alveolar NO (CAwNO). Objectives: To determine the effect of natural allergen exposure, a proinflammatory stimulus, on the shape of the concentration-response curve to AMP and NO production in airway and alveolar sites. Methods: Airway responsiveness to high concentrations of methacholine and AMP, J′awNO and CAwNO values were obtained in 31 subjects with pollen allergy and in 11 healthy controls. Subjects with pollen allergy were studied before and at the height of the pollen season whereas healthy controls were tested on one occasion only. Results: In the group with pollen allergy, natural pollen exposure increased J′awNO (p = 0.03), but had no effect on CAwNO (p = 0.12). In the 18 subjects with pollen allergy who showed a response plateau to AMP in at least one period, the response plateau to AMP increased from a mean of 13.4% (95% CI: 8.2–18.5) out of season to 22.5% (95% CI: 15.5–29.4, p = 0.004) during the pollen season. Similar results were obtained with methacholine. Compared with healthy controls, subjects with pollen allergy had a higher response plateau and higher J′awNO values. Conclusions: These findings suggest that inflammatory changes induced by natural allergen exposure in sensitized subjects are predominantly located in the airways and associated with modifications in the shape of the concentration-response curve to direct and indirect agonists.

Introduction

It is widely appreciated that asthma is an inflammatory disease of the airways associated with airway hyperresponsiveness. Methacholine challenge has been widely used for the detection and quantitation of airway responsiveness, and the response to this bronchoconstrictor agent is commonly expressed as the provocative concentration (PC20) or dose (PD20) causing a 20% fall in forced expiratory volume in 1 s (FEV1). However, airway hyperresponsiveness can be defined as the tendency of the airways to narrow too easily and too much in response to a wide variety of provoking stimuli [1]. Airway narrowing...
that occurs too easily (airway sensitivity) is assessed by measuring PC_{20}, but this measure does not assess excessive bronchoconstriction [2], which in some cases may lead to life-threatening attacks and which is reflected by the response plateau level. In addition, it has been suggested that the mechanisms that modulate sensitivity and the response plateau level are at least partially different [3]. Therefore, complete description of the dose-response curve requires two parameters: one for sensitivity and one for excessive bronchoconstriction (response plateau level).

Methacholine and histamine are the most frequently used spasmogens for the investigation of bronchial responsiveness. These two agonists cause bronchoconstriction by a direct effect on airway smooth muscle cells. In contrast, inhaled adenosine 5’-monophosphate (AMP) acts indirectly, causing ‘primed’ mast cell degranulation and the release of histamine and other mediators with subsequent smooth muscle contraction [4]. Thus, AMP may provide additional information about airway inflammation and cellular activation state in asthma [5].

On the other hand, exhaled nitric oxide (NO) levels are increased in asthma [6], and are correlated with the number of eosinophils in the lower respiratory tract [7]. Although this correlation is quite weak, exhaled NO has been proposed as a noninvasive marker of airway inflammation in asthma [8]. The plateau NO concentration measured during exhalation at the constant flow rate of 50 ml/s, referred as FE_{NO,50}, has been extensively studied as a potential index of airway inflammation. However, phenotyping asthma inflammation is a hot topic, and the interest extends beyond the identification of predominant inflammatory cells to the localization of inflammation [9] (central vs. peripheral airways). Therefore, special interest has focused on the possibility of modeling NO production to calculate how much of the NO that is measured in exhaled air originates from alveolar and from bronchial sources [10].

Previous investigations have demonstrated that, in sensitized subjects, natural allergen exposure (a proinflammatory stimulus) is associated with a significant increase in the response plateau to methacholine [11, 12] and with a significant increase in exhaled FE_{NO,50} [13, 14]. No information is available, however, on allergen-induced changes in the response plateau to AMP and in CA_{NO} and J’aw_{NO}. We hypothesized that allergen exposure in sensitized subjects is associated with changes in the shape of the concentration-response curve to AMP and with possibly distinct increases in CA_{NO} and J’aw_{NO}. To confirm this hypothesis, we have identified the response plateau and NO production in bronchial and alveolar sites before and at the height of the pollen season in a group of subjects with pollen allergy.

**Subjects and Methods**

**Study Subjects**

A total of 42 subjects volunteered for this study. Thirty-one patients with seasonal allergic rhinitis, with or without intermittent asthma, were recruited from the Allergy Clinic of our institution. Asthma was diagnosed by the presence of symptoms of wheeze, breathlessness or cough plus methacholine airway hyperresponsiveness (PC_{20} ≤ 8 mg/ml) or an improvement in FEV\textsubscript{1} from a baseline of ≥15% after 200 µg inhaled salbutamol during the pollen season. All subjects with asthma were treated with short-acting inhaled β\textsubscript{2}-agonists as required. Skin prick tests showed positive responses (>3 mm wheal diameter) to grass, *Olea europea* and/or *Parietaria judaica* pollens in all the subjects. Nine subjects were also sensitized to perennial allergens although they had no symptoms out of the pollen season. A control group of 11 healthy subjects was also studied; they were recruited among volunteers in the laboratory and among students. Selection criteria for this group included no history of asthma, chronic rhinitis, atopic eczema, or other relevant disease.

All 42 subjects were nonsmokers and had baseline FEV\textsubscript{1} >70% predicted. In case of recent respiratory tract infection, enrolment in the study was postponed for at least 4 weeks. The study protocol was approved by the ethics committee of Dr. Peset University Hospital and all subjects provided informed consent.

**Study Design**

Patients were first evaluated between mid-January and the end of February, before the pollen season had begun in Valencia, Spain. During this period, patients had 3 laboratory visits. At the first visit, all patients were evaluated for suitability and spirometry was performed. At each of the next 2 visits (3–7 days apart), spirometry and concentration-response studies with either methacholine or AMP were performed on separate days, with the order of challenge randomized. Exhaled NO was measured at the second visit. Patients returned to the laboratory at the height of the pollen season between April and June. During this period, patients attended 2 laboratory visits. At each visit, exhaled NO, spirometry and concentration-response studies with either methacholine or AMP were performed. The same determinations were performed in healthy controls on one occasion only.

The pollen season period was estimated according to atmospheric pollen counts obtained in the Valencia area [15] (fig. 1).

**Study Variables**

**Inhalation Challenge Tests.** Spirometry [16] and bronchial challenge tests [17] (Mefar MB3; Brescia, Italy) as previously reported [14]. Methacholine and AMP (Sigma-Aldrich, St. Louis, Mo., USA) were dissolved freshly in 0.9% saline solution to produce doubling concentration ranges of 0.39 to 100 mg/ml for methacholine and 6.25–1,600 mg/ml for AMP. The test was interrupted when a 40% decrease in FEV\textsubscript{1} from the value obtained after saline solution administration was recorded or when the highest concentration
was administered. A response plateau was considered to be present if 3 or more data points for the highest concentrations of agonist fell within a 5% response range. The level of the maximal FEV\textsubscript{1} response was calculated only in those subjects who showed falls in FEV\textsubscript{1}>5% and was obtained by averaging the data points on the plateau. In subjects who showed falls in FEV\textsubscript{1}>40% without evidence of a plateau, the response plateau values were assigned to percent decline in FEV\textsubscript{1} at the end of the protocol. Two subjects with a plateau during the methacholine and AMP challenges performed out of season lost the plateau during the pollen season. In these subjects, the response plateau values were assigned to percent decline in FEV\textsubscript{1} at the end of challenge. A PC\textsubscript{20} value of 100 mg/ml for methacholine and 1,600 mg/ml for AMP was assigned to these subjects in whom FEV\textsubscript{1} dropped <20% even when the highest concentration of agonist was used (censored values). All PC\textsubscript{20} values were log-transformed before analysis and are presented as geometric means. Changes in PC\textsubscript{20} are expressed in terms of doubling concentrations of methacholine or AMP calculated as $\log\text{PC}_{20}/\log 2$.

**NO Measurements.** Exhaled NO was measured with a chemiluminescence technique (Niox; Aerocrine, Stockholm, Sweden) according to ATS/ERS standards [18], with the exception of the choice of exhalation flow rates, which were 100, 200 and 300 ml/s. To enable the subjects to achieve the target flow rate, dynamic flow resistors were used. The exhalation times varied from 6 to 10 s, depending on the exhalation flow rate, and exhaled NO was always measured during the last 3 s of the exhaled NO maneuver. The average of two values performed at each of the three flow rates was recorded. The technique of Tsoukias and George [19] was used to calculate J\textsuperscript{aw}NO (pl/s) (y intercept) and steady-state CA\textsubscript{NO} concentration (ppb) (slope) using a linear regression. CA\textsubscript{NO} was adjusted for the trumpet shape of the airway tree and axial diffusion from central to peripheral airways (CA\textsubscript{NOcorr}) with the following equation [20]: $\text{CA}_{\text{NOcorr}} (\text{ppb}) = \text{CA}_{\text{NO}} (\text{ppb}) - J^{\text{aw} \text{NO}} (\text{pl/s})/860$.

**Statistical Analysis**

The primary outcome of the study was the response plateau to AMP. Secondary outcomes were the response plateau to methacholine, PC\textsubscript{20} for AMP and methacholine and exhaled NO (CA\textsubscript{NO} and J\textsuperscript{aw}NO). The sample size requirement of this study was calculated considering a difference of 7% in the response plateau to AMP as clinically relevant. Based on a calculated SD of 7% for the response plateau to AMP from previous studies [21], it was estimated that 18 patients with a plateau during at least one AMP challenge would be required to provide 80% power at the two-sided 0.05 level. Given the prevalence of plateaus identified in previous studies [21], it was estimated that 30 patients would be tested to identify 18 with plateaus.

Comparisons of the characteristics of the two groups were performed by unpaired Student t tests for continuous data and by Fisher exact tests for binary variables. Changes in the response plateau, PC\textsubscript{20} and exhaled NO in subjects with pollen allergy were assessed by the paired t test. Correlations were explored using the Pearson correlation test. p values are two-sided, and values <0.05 were considered statistically significant.

**Table 1. Subject characteristics and prevalence of bronchoconstriction**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Pollen allergy</th>
<th>Healthy</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects, n</td>
<td>31</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allergic rhinitis, n</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allergic rhinitis + asthma, n</td>
<td>11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>48 (44–52)</td>
<td>31 (22–40)</td>
<td>0.0002</td>
</tr>
<tr>
<td>Male/female gender, n</td>
<td>13/18</td>
<td>5/6</td>
<td>0.98</td>
</tr>
<tr>
<td>Duration of symptoms, years</td>
<td>14.9 (11.3–18.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV\textsubscript{1}, % predicted</td>
<td>107.1 (101.4–112.7)</td>
<td>108.0 (99.4–116.5)</td>
<td>0.86</td>
</tr>
<tr>
<td>FEV\textsubscript{1}/FVC, %</td>
<td>73.6 (70.9–76.2)</td>
<td>80.4 (76.4–84.5)</td>
<td>0.08</td>
</tr>
</tbody>
</table>

Data are presented as means, and means and 95% CI (in parentheses). FVC = Forced vital capacity.
Subjects with pollen allergy were significantly older and tended to have lower FEV₁/FVC % values than healthy controls. The two groups were similar with regard to sex and baseline FEV₁ (table 1). A total of 18 subjects with pollen allergy (9 with allergic rhinitis and 9 with allergic rhinitis and associated asthma) were responsive (FEV₁ fall ≥ 20%) to methacholine whereas only 9 subjects (4 with allergic rhinitis and 5 with allergic rhinitis and asthma) were responsive to AMP. Responsiveness to AMP and methacholine was identified in 1 and 4 healthy controls, respectively.

### Differences in Airway Responsiveness and NO Indexes between Subjects with Pollen Allergy and Healthy Controls

Compared with healthy controls, subjects with pollen allergy had lower values of PC₂₀ AMP (p < 0.01 for season and p = 0.014 for out of season) and PC₂₀ methacholine (p < 0.001 for both periods), and higher values of response plateaus to AMP (p < 0.0001 for season and p = 0.012 for out of season) and J'awNO (p < 0.0001 for both periods) (table 2, fig. 2). The response plateau to methacholine was significantly higher in subjects with pollen allergy than in healthy controls during the pollen season only (p = 0.015) (table 2). No significant differences were observed...
between the two groups regarding CA\textsubscript{NO} (p = 0.17 during the pollen season and p = 0.51 out of season).

\textit{Modifications in Airway Responsiveness and NO Indexes during the Pollen Season}

The mean FEV\textsubscript{1} values for subjects with pollen allergy was 3.09 liters (95% CI: 2.75–3.43) out of season, compared with 3.04 liters (95% CI: 2.7–3.37, p = 0.38) during the pollen season.

In the group with pollen allergy, methacholine and AMP PC\textsubscript{20} values decreased significantly during the pollen season (p = 0.008 for methacholine and p = 0.002 for AMP, table 2). Pollen-induced changes in methacholine and AMP PC\textsubscript{20} values were not significantly different, the mean difference being 0.32 doubling concentrations (95% CI: –0.24 to 0.87 doubling concentrations, p = 0.25). Similar results were obtained when those subjects with censored PC\textsubscript{20} values in both periods were excluded from the analysis (data not shown).

In the 18 subjects with pollen allergy who showed plateaus in at least one period, the response plateau to AMP increased from a mean of 13.4% (95% CI: 8.2–18.5) out of season to 22.5% (95% CI: 15.5–29.4, p = 0.004, fig. 3) during the pollen season; the response plateau to methacholine increased from 17.6% (95% CI: 13.4–21.8) out of season to 21.8% (95% CI: 15.7–27.9, p = 0.02) during the pol-

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure3.png}
\caption{Individual values for the response plateau to methacholine (a) and AMP (b) before and during the pollen season in subjects who showed plateaus in at least one period. Horizontal lines are means.}
\end{figure}

\begin{table}
\centering
\caption{Level of plateau and markers in exhaled air in subjects with allergic rhinitis and in those with asthma}
\begin{tabular}{lccc}
\hline
Variable & Asthma & & Allergic rhinitis \\
 & out of season & during season & out of season & during season \\
\hline
Plateau level, % & & & & \\
Methacholine & 23.2 (15.2–31.7) & 33.5 (20.0–46.9)* & 15.4 (10.4–20.4) & 17.3 (11.5–23.1) \\
AMP & 13.6 (5.0–23.4) & 26.9 (12.2–41.6)* & 13.2 (6.0–20.4) & 20.1 (11.9–28.3)* \\
Exhaled NO & & & & \\
J\textsuperscript{awNO}, pl/s & 2,266 (1,005–3,528) & 2,847 (1,412–4,282) & 1,880 (1,093–2,667) & 2,360 (1,496–3,225)** \\
CA\textsubscript{NO}, ppb & 1.3 (0.3–2.3) & 0.8 (0.1–1.6) & 0.8 (0.5–1.1) & 0.7 (0.4–1.0) \\
\hline
\end{tabular}
\begin{flushright}
Data are given as means and 95% CI (in parentheses). * p < 0.05 vs. out of season; ** p < 0.01 vs. out of season.
\end{flushright}
\end{table}
Differences in Pollen-Induced Changes in the Plateau and Exhaled Markers between Subjects with Allergic Rhinitis Alone and Those with Concomitant Asthma

Both in asthmatics and subjects with allergic rhinitis, the response plateau to each bronchoconstrictor agent and $\text{J'awNO}$ values increased during the pollen season (table 3). Furthermore, the pollen-induced change in the response plateau to methacholine was significantly higher in the group with asthma than in the group with allergic rhinitis, the mean difference being 8.3% (95% CI: 2.3–14.3, p = 0.009). By contrast, pollen-induced changes in both the response plateau to AMP and $\text{J'awNO}$ values were similar in the two groups, the mean difference being 6.4% (95% CI: 5.2–18.1, p = 0.26) and 9.53 pl/s (95% CI: –8.7 to 27.8, p = 0.29), respectively.

Correlations

In subjects with pollen allergy, there was a weak correlation between AMP PC$_{20}$ values and $\text{J'awNO}$ (out of season, $r = -0.56$, p = 0.003; season, $r = -0.50$, p = 0.008), as well as between the response plateau to AMP and $\text{J'awNO}$ (out of season, $r = 0.54$, p = 0.004; season, $r = 0.42$, p = 0.03). Furthermore, there was a trend to a correlation between pollen-induced changes in $\text{J'awNO}$ and in responsiveness to AMP ($r = 0.42$, p = 0.03 for PC$_{20}$ and $r = 0.48$, p = 0.01 for plateau; fig. 4). All these correlations were not significant for methacholine. No other correlations were detected.

Discussion

The results of the present study confirm that, in pollen-sensitive subjects with allergic rhinitis associated or not with intermittent asthma, natural exposure to pollen is associated with a significant increase in airway sensitivity (decreased PC$_{20}$ value) to both methacholine and AMP, as well as with a significant increase in the response plateau to methacholine. The new findings are that natural pollen exposure in sensitized subjects is also associated with a significant increase in the response plateau identified with AMP and in $\text{J'awNO}$ without concomitant modifications in $\text{CA_NO}$. Furthermore, the response plateau to AMP and $\text{J'awNO}$ values were significantly higher in subjects with pollen allergy than in healthy controls.

To the best of our knowledge, this is the first study designed to identify the effect of natural allergen exposure on the response plateau to AMP. Our results demonstrate that the allergen-induced increase in the plateau to AMP is of similar magnitude to that detected with methacho-
Natural Pollen Exposure Increases the Response Plateau to AMP and J'awNO

The presence of airway hyperresponsiveness to AMP and increased J'awNO in our subjects with pollen allergy, even when these parameters were obtained out of the pollen season, suggests that airway inflammation is present even when patients are not exposed to the relevant allergens. However, this study has some limitations that are important to consider. Firstly, our patients with pollen allergy were significantly older than healthy controls. Therefore, although the effect of age on AMP responsiveness has not been studied, we cannot exclude the possibility that differences in these parameters between the two groups might be explained, at least in part, by differences in age. Secondly, it has recently been reported [23] that NO concentration measured at 50 ml/s and CA\textsubscript{NO}, but not bronchial NO production, increases with age ≥60 years in normal control subjects. Thus, differences in J'awNO between subjects with pollen allergy and healthy controls cannot be explained by differences in age. Thirdly, the effect of natural pollen exposure on airway responsiveness, CA\textsubscript{NO} and J'awNO were identified comparing values during the pollen season and out of season. It is possible that the inclusion of a control group of subjects with nonatopic asthma might increase the relevance of our observations. This should be investigated in future studies. Finally, our healthy controls were studied on one occasion only and, therefore, the reproducibility of our results in this population is unknown.

In summary, our current observations have shown an increase in both the response plateau and J'awNO in subjects with pollen allergy compared with healthy controls. In subjects with pollen allergy, both parameters increased significantly following natural allergen exposure. These results suggest that natural allergen exposure in sensitized subjects induces inflammatory changes in the airways (but not in the lung periphery) and modifications in the shape of the concentration-response curve to direct and indirect agonists.

Acknowledgements

The authors wish to thank Regiduria de Sanidad (Seccion de Programas de Salud) from the Ayuntamiento de Valencia for providing data on atmospheric pollen counts, and Diater Laboratorios (Madrid, Spain) for help and collaboration. The technical assistance of Rocio Rojas and Ana Lucas is gratefully acknowledged.
References


